Prediction Market Platforms Face Legal Challenges as 16 States Escalate Regulatory Battle China Calls for APEC Economic Cooperation as Commerce Minister Skips Meeting Over Urgent Official Business SmallCap Biotech Stocks Key Sector Trends and Investor Considerations China Calls for APEC Trade Cooperation as Commerce Minister Skips Opening Due to Urgent Official Business NSE IPO Exchange Eyes Early June Filing with Securities Regulator Jim Hensons Creature Shop Opens to Public After Decades of Secrecy WMS Q1 2026 Earnings EPS Surges Past Estimates Despite Negative Market Reaction RLMD Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Continues RD Investment GOOG Q1 2026 Earnings EPS Misses Estimates Amid Continued AI Investment PEG Q1 2026 Earnings Utility Giant Beats Estimates as Operational Efficiency Drives Profit GRRR Q4 2025 Earnings EPS Misses Estimates Sharply Yet Stock Surges Kyndryl KD Q1 2026 Earnings EPS Misses Expectations Stock Rises Despite Surprise AbbVie ABBV Shows Modest Gain as Biotech Sector Stabilizes NCR Atleos NATL Holds Steady Near Support as Volume Remains Light Nuveen Municipal High Income Opportunity Fund NMZ Edges Lower on Rate Concerns Holds Near Midpoint IP Strategy Holdings Inc IPST Faces Sharp Decline Testing Key Support Levels CollPlant Biotechnologies CLGN Slips Slightly as Stock Tests Key Support near 040 ZM Q1 2026 Earnings Strong EPS Beat Amid Revenue Discrepancy Stock Dips Progyny Inc PGNY Q1 2026 Earnings EPS Misses Estimates as Fertility Benefits Utilization Pressures Margins MED Q1 2026 Earnings EPS Surpasses Estimates Amid Cost Management Efforts United Community Banks Inc UCB Q1 2026 Earnings Slight Earnings Miss Meets Modest Share Price Uptick OKUR Q1 2026 Earnings WiderthanExpected Loss Reflects RD Investment Ally Financial Q1 2026 Earnings EPS Surpasses Estimates by 165 Shares Edge Higher OpenAI Reportedly Prepares for Confidential IPO Filing Signaling Leadership in AI Race First Bancorp FBNC Q1 2026 Earnings EPS Edges Past Expectations Amid Quiet Market Reaction Corvus Pharmaceuticals CRVS Climbs 230 as Shares Approach Resistance